About

Twobull MeDiTherapy is a medical device biotech company.

Solution & Product

Novel diagnostic blood test for the detection and classification of abdominal and thoracic aortic aneurysms that makes early detection possible. This product is the first of its kind worldwide. Our proposed diagnostic test will offer a valuable tool for clinical doctors in decision making for the management of the disease, because it carries also prognostic properties on top of its diagnostic abilities.

Innovation & Scalability

The company's is developing a novel unique blood diagnostic test for human aortic aneurysm. The current solutions for the diagnosis of human aortic aneurysms are based only on imaging techniques( Ultrasound, MRI and CT scan.) It is the first diagnostic blood test for the detection of aortic aneurysms worldwide. The product has the potential to be used for the screening of the global adult population in order to detect patients with aortic aneurysms, therefore all the developed countries with public health systems, private insurance companies and programs for preventive medicine are our potential markets for expansion.

Traction & achievements

The company has received seed funding to complete the development of the prototype diagnostic blood test and the multicenter clinical study in order to identify the performance characteristics, prepare the technical file for the CE Mark certification according to the IVDR and obtain 13485:2016 ISO Certification for the Design, Production and Distribution of medical devices.

Team & Why Us

Toumpoulis Stavros, DDS. Stavros is President and Founder of 2bullMeDiTherapy, Graduate studies in Dental School of Aristoteles University Of Thessaloniki Toumpoulis Ioannis , Vise President and Founder. Prof. Doctor Ioannis Toumpoulis has over 10 years of experience in cardiothoracic surgery. He has been an assistant Professor of Cardiothoracic Surgery at the National and Kapodistrian University of Athens for 10 years. Kanistras Dimitrios , CEO. Dimitris studied Chemical Engineering, he has specialized in material technology and has conducted research in catalysis.

Funding Needs

The company has received sufficient seed funding of 1M euros for the current milestones of the company. A new funding round will be considered in Q4 of 2021.